Natus seeks FDA 510(k) clearance for its highly anticipated point-of-care EEG solution
Blog

Natus seeks FDA 510(k) clearance for its highly anticipated point-of-care EEG solution


MIDDLETON, Wis., Oct. 10, 2024 /PRNewswire/ — Natus Medical Incorporated announced it has submitted an FDA 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Natus point-of-care EEG device.

The rapid deploy decision-support tool is designed to quickly help identify non-convulsive seizures (NCSs) and status epilepticus in acute care environments, supporting rapid intervention and streamlining treatment decisions to improve patient outcomes.